Pharming Group (NASDAQ:PHAR) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Pharming Group (NASDAQ:PHAR) in a research report report published on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $14.00 price target on the stock.

Several other analysts have also recently commented on PHAR. Oppenheimer decreased their price target on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, October 28th. HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of Pharming Group in a report on Thursday, October 24th.

Pharming Group Stock Performance

Shares of PHAR opened at $9.27 on Monday. Pharming Group has a one year low of $6.65 and a one year high of $13.20. The company has a 50-day moving average of $8.23 and a two-hundred day moving average of $8.14. The stock has a market cap of $628.83 million, a price-to-earnings ratio of -35.65 and a beta of 0.05. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its holdings in Pharming Group (NASDAQ:PHAR) by 75.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,110 shares of the company’s stock after acquiring an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.